Starpharma do not need more secret partner 6 year pre-clinical research agreements. Well Jackie Fairley might like them because it keeps the KPIs and bonuses ticking over but it does sweet FA for shareholders.
Rubber on the road licencing agreements do not occur from ‘networking’ at ASCO. So let’s put that to bed. Nice desperate attempt at a pump though…
ASCO 22 and Starpharma, page-4
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $45.99M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 12.0¢ | 10.5¢ | $114.6K | 998.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 171158 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 204 | 1 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |